Nektar Therapeutics (NKTR) - Total Assets
Based on the latest financial reports, Nektar Therapeutics (NKTR) holds total assets worth $763.27 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check NKTR cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Nektar Therapeutics - Total Assets Trend (1994–2025)
This chart illustrates how Nektar Therapeutics's total assets have evolved over time, based on quarterly financial data. Explore Nektar Therapeutics (NKTR) investment intensity to see how much of total assets are deployed in long-term investments.
Nektar Therapeutics - Asset Composition Analysis
Current Asset Composition (December 2025)
Nektar Therapeutics's total assets of $763.27 Million consist of 95.0% current assets and 5.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.4% |
| Accounts Receivable | $1.78 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1994–2025)
This chart illustrates how Nektar Therapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Nektar Therapeutics (NKTR) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nektar Therapeutics's current assets represent 95.0% of total assets in 2025, an increase from 86.1% in 1994.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2025, down from 61.1% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Nektar Therapeutics Competitors by Total Assets
Key competitors of Nektar Therapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Nektar Therapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.21 | 3.24 | 8.06 |
| Quick Ratio | 10.21 | 3.24 | 7.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $531.33 Million | $158.98 Million | $925.12 Million |
Nektar Therapeutics - Advanced Valuation Insights
This section examines the relationship between Nektar Therapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.79 |
| Latest Market Cap to Assets Ratio | 7.33 |
| Asset Growth Rate (YoY) | -7.7% |
| Total Assets | $280.41 Million |
| Market Capitalization | $2.06 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Nektar Therapeutics's assets at a significant premium (7.33x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Nektar Therapeutics's assets decreased by 7.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nektar Therapeutics (1994–2025)
The table below shows the annual total assets of Nektar Therapeutics from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $280.41 Million | -7.72% |
| 2024-12-31 | $303.85 Million | -23.66% |
| 2023-12-31 | $398.03 Million | -43.99% |
| 2022-12-31 | $710.60 Million | -36.39% |
| 2021-12-31 | $1.12 Billion | -27.40% |
| 2020-12-31 | $1.54 Billion | -22.18% |
| 2019-12-31 | $1.98 Billion | -8.04% |
| 2018-12-31 | $2.15 Billion | +322.54% |
| 2017-12-31 | $508.87 Million | -10.55% |
| 2016-12-31 | $568.87 Million | +13.31% |
| 2015-12-31 | $502.06 Million | +13.69% |
| 2014-12-31 | $441.62 Million | +1.63% |
| 2013-12-31 | $434.53 Million | -12.71% |
| 2012-12-31 | $497.79 Million | -17.93% |
| 2011-12-31 | $606.55 Million | +16.37% |
| 2010-12-31 | $521.23 Million | -9.43% |
| 2009-12-31 | $575.52 Million | +2.67% |
| 2008-12-31 | $560.54 Million | -22.70% |
| 2007-12-31 | $725.10 Million | -5.61% |
| 2006-12-31 | $768.18 Million | -10.53% |
| 2005-12-31 | $858.55 Million | +15.25% |
| 2004-12-31 | $744.92 Million | +20.77% |
| 2003-12-31 | $616.79 Million | +1.67% |
| 2002-12-31 | $606.64 Million | -9.08% |
| 2001-12-31 | $667.24 Million | +5.99% |
| 2000-12-31 | $629.54 Million | +177.57% |
| 1999-12-31 | $226.81 Million | +68.63% |
| 1998-12-31 | $134.50 Million | +12.30% |
| 1997-12-31 | $119.76 Million | +188.58% |
| 1996-12-31 | $41.50 Million | +78.88% |
| 1995-12-31 | $23.20 Million | +34.88% |
| 1994-12-31 | $17.20 Million | -- |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosi… Read more